These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 35914662)

  • 1. Omalizumab for treatment of idiopathic angioedema.
    Goswamy VP; Lee KE; McKernan EM; Fichtinger PS; Mathur SK; Viswanathan RK
    Ann Allergy Asthma Immunol; 2022 Nov; 129(5):605-611.e1. PubMed ID: 35914662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Maurer M; Weller K
    Allergy; 2018 Mar; 73(3):576-584. PubMed ID: 29058822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.
    Zazzali JL; Kaplan A; Maurer M; Raimundo K; Trzaskoma B; Solari PG; Antonova E; Mendelson M; Rosén KE
    Ann Allergy Asthma Immunol; 2016 Oct; 117(4):370-377.e1. PubMed ID: 27424128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of omalizumab in Chinese patients with anti-histamine refractory chronic spontaneous urticaria.
    Yuan W; Hu S; Li M; Yang L; Liu L; Zheng M; Guo Z; Song Z; Zhang C; Diao Q; Xu J; Richard A; Patwardhan M; Lyu T; Uddin A; Fogel R; Ligueros-Saylan M; Zheng J
    Dermatol Ther; 2022 Apr; 35(4):e15303. PubMed ID: 34984792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
    Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
    J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
    Giménez-Arnau AM
    Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
    Ghazanfar MN; Holm JG; Thomsen SF
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials.
    Zhao ZT; Ji CM; Yu WJ; Meng L; Hawro T; Wei JF; Maurer M
    J Allergy Clin Immunol; 2016 Jun; 137(6):1742-1750.e4. PubMed ID: 27040372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of chronic spontaneous urticaria with omalizumab.
    Pinto Gouveia M; Gameiro A; Pinho A; Gonçalo M
    Clin Exp Dermatol; 2017 Oct; 42(7):735-742. PubMed ID: 28649751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab vs. placebo in the management of chronic idiopathic urticaria: a systematic review.
    Carrillo DC; Borges MS; García E; Egea E; Serrano CD
    World Allergy Organ J; 2014; 7(1):72. PubMed ID: 25566332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema.
    Maurer M; Sofen H; Ortiz B; Kianifard F; Gabriel S; Bernstein JA
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1056-1063. PubMed ID: 27911016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers.
    Türk M; Carneiro-Leão L; Kolkhir P; Bonnekoh H; Buttgereit T; Maurer M
    J Allergy Clin Immunol Pract; 2020 Jan; 8(1):113-124. PubMed ID: 31374358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
    Kocatürk E; Başkan EB; Küçük ÖS; Özdemir M; Örnek S; Can PK; Haşal E; Engin B; Atakan N; Alpsoy E
    An Bras Dermatol; 2022; 97(5):592-600. PubMed ID: 35853771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligelizumab for Chronic Spontaneous Urticaria.
    Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
    N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series.
    Ari A; Levy Y; Segal N; Maoz-Segal R; Benor S; Broides A; Horev A; Epstein-Rigbi N; Agmon-Levin N; Marcus N
    Pediatr Dermatol; 2020 Nov; 37(6):1051-1054. PubMed ID: 32951239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment-Results From CURE.
    Buttgereit T; Vera C; Aulenbacher F; Church MK; Hawro T; Asero R; Bauer A; Bizjak M; Bouillet L; Dissemond J; Fomina D; Giménez-Arnau AM; Grattan C; Gregoriou S; Kulthanan K; Kasperska-Zajac A; Kocatürk E; Makris M; Kolkhir P; Weller K; Magerl M; Maurer M
    J Allergy Clin Immunol Pract; 2023 Nov; 11(11):3515-3525.e4. PubMed ID: 37604426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Omalizumab for Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Jia HX; He YL
    Am J Ther; 2020; 27(5):e455-e467. PubMed ID: 32427616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria.
    Hide M; Park HS; Igarashi A; Ye YM; Kim TB; Yagami A; Roh J; Lee JH; Chinuki Y; Youn SW; Lee SK; Inomata N; Choi JH; Fukunaga A; Wang J; Matsushima S; Greenberg S; Khalil S
    J Dermatol Sci; 2017 Jul; 87(1):70-78. PubMed ID: 28366435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.